Belite Bio, Inc. Sponsored ADR (NASDAQ:BLTE) Receives $203.00 Average Target Price from Brokerages

Posted by George Bondi on Aug 14th, 2026

Shares of Belite Bio, Inc. Sponsored ADR (NASDAQ:BLTE – Get Free Report) have been given a consensus recommendation of “Moderate Buy” by the eight brokerages that are covering the stock, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, six have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 month price objective among analysts that have issued ratings on the stock in the last year is $204.40.

Several brokerages recently commented on BLTE. HC Wainwright upped their price target on shares of Belite Bio from $200.00 to $214.00 and gave the company a “buy” rating in a report on Wednesday. Mizuho decreased their price objective on shares of Belite Bio from $223.00 to $215.00 and set an “outperform” rating for the company in a research note on Tuesday, May 26th. Weiss Ratings restated a “sell (d-)” rating on shares of Belite Bio in a research report on Monday, July 6th. Benchmark reaffirmed a “buy” rating on shares of Belite Bio in a research note on Friday, May 22nd. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of Belite Bio in a report on Wednesday.

View Our Latest Report on BLTE

Belite Bio Stock Down 7.1%

NASDAQ BLTE opened at $166.26 on Friday. Belite Bio has a 52 week low of $60.00 and a 52 week high of $200.00. The firm has a market capitalization of $6.66 billion, a price-to-earnings ratio of -65.72 and a beta of -1.22. The company has a fifty day moving average of $152.11 and a two-hundred day moving average of $159.84.

Belite Bio (NASDAQ:BLTE – Get Free Report) last announced its earnings results on Friday, May 15th. The company reported ($0.34) earnings per share for the quarter, beating the consensus estimate of ($0.60) by $0.26. Equities research analysts anticipate that Belite Bio will post -3.17 EPS for the current year.

Insider Buying and Selling

In other Belite Bio news, insider Hendrik Peter Scholl sold 10,000 shares of the company’s stock in a transaction on Thursday, June 18th. The stock was sold at an average price of $145.24, for a total value of $1,452,400.00. Following the transaction, the insider owned 15,000 shares of the company’s stock, valued at $2,178,600. This represents a 40.00% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. 13.29% of the stock is owned by company insiders.

Institutional Trading of Belite Bio

Several institutional investors and hedge funds have recently made changes to their positions in the business. Affinity Asset Advisors LLC grew its stake in Belite Bio by 225.0% in the 1st quarter. Affinity Asset Advisors LLC now owns 65,000 shares of the company’s stock worth $10,364,000 after acquiring an additional 45,000 shares in the last quarter. Western Standard LLC bought a new stake in shares of Belite Bio during the fourth quarter valued at approximately $9,602,000. The Manufacturers Life Insurance Company bought a new stake in shares of Belite Bio during the first quarter valued at approximately $3,125,000. Renaissance Technologies LLC purchased a new stake in shares of Belite Bio in the first quarter valued at approximately $8,291,000. Finally, Eventide Asset Management LLC boosted its holdings in shares of Belite Bio by 96.1% in the fourth quarter. Eventide Asset Management LLC now owns 383,091 shares of the company’s stock valued at $61,279,000 after purchasing an additional 187,779 shares during the period. 0.53% of the stock is currently owned by institutional investors.

Belite Bio News Summary

Here are the key news stories impacting Belite Bio this week:

Positive Sentiment: The FDA granted priority review to Belite Bio’s tinlarebant New Drug Application for Stargardt disease. The accelerated review sets an expected decision date in February 2027 and follows positive Phase 3 data, potentially shortening the path to commercialization for the company’s lead program. BLTE Stock Rises as FDA Grants Priority Review to Tinlarebant NDA
Positive Sentiment: HC Wainwright raised its price target to $214 from $200 and maintained a Buy rating, signaling continued analyst confidence in tinlarebant’s commercial potential. Belite Bio Price Target Increase
Positive Sentiment: Second-quarter results exceeded expectations: Belite Bio reported a loss of $0.54 per share versus the consensus estimate of a $0.73 loss. The earnings beat may support sentiment, while management’s corporate update and earnings call provided additional detail on the company’s development programs. Belite Bio Second Quarter 2026 Results
Neutral Sentiment: Belite Bio remains a clinical-stage biotechnology company, so its valuation and stock performance remain highly dependent on regulatory decisions, clinical execution and the future launch of tinlarebant. Belite Bio Q2 2026 Earnings Call Transcript
Negative Sentiment: The company continues to report net losses, and analysts expect a full-year loss. With shares trading near their yearly high and at a loss-based price-to-earnings valuation, investors may be taking profits despite the positive FDA and earnings developments.

Belite Bio Company Profile

(Get Free Report)

Belite Bio, Inc (NASDAQ: BLTE) is a clinical-stage biotechnology company focused on discovering and developing small molecule therapeutics for metabolic and inflammatory diseases. Leveraging a proprietary drug-discovery platform, the company aims to address conditions such as nonalcoholic steatohepatitis (NASH) and obesity by targeting pathways involved in fibrosis, inflammation and metabolic regulation.

Belite Bio’s pipeline includes multiple candidates in preclinical and early clinical development stages.